Background
Anti-type I interferon (IFN-I) neutralizing autoantibodies (NABs) have been associated with an increased risk of life-threatening viral infections, including SARS-CoV-2, influenza virus and more recently West Nile virus. Given the detrimental role of IFN-I in HIV-1 infection, it is imperative to investigate anti-IFN NABs and associated IFN pathway modulation in people living with HIV (PLWH). Therefore, we investigated the prevalence of anti-IFN-I NABs in a cohort of PLWH, and examined their specificity, fluctuation over time, biological significance and clinical implications.
Methods
Blood samples were collected from 280 virologically suppressed ART-treated PLWH at the Policlinico Umberto I, hospital of Sapienza in Rome, Italy. Serum samples were tested for the detection of NABs against IFN-α, -β and -ω using an antiviral bioassay. Longitudinal measurements of NABs over a 1-year period were carried out in serum samples from those patients with anti-IFN-I NABs. Expression levels of the IFN induced antiretroviral restriction factors, APOBEC 3G/3F and ISG15, were measured by RT/real time PCR in PBMC from NAB-positive and age- and sex-matched NAB-negative PLWH (n=16).
Results
Anti-IFN-I NABs was detected in 3.9% of PLWH (11/280). The range of NAB levels against IFN-α was very wide (53-530000 tenfold reduction units [TRU/mL]). We found that 45% (5/11) of sera containing anti-IFN-I NABs were able to neutralize IFN-ω but not IFN-β. All NABs-positive PLWH were male, with a median age of 65 years (range 30-78) and median nadir CD4+ T cell counts (cells/µl) and CD4+ T cell counts of 190 and 500, respectively. Four PLWH had been hospitalized for severe SARS-CoV-2 infection (two requiring mechanical ventilation and one with a fatal outcome); two individuals had Kaposi’s sarcoma and one had AIDS dementia complex with oropharyngeal candidiasis. Reduced levels of APOBEC3G/3F and ISG15 mRNA were observed in PBMC from anti-IFN NABs positive PLWH compared to negative PLWH (p<0.05). Longitudinal evaluation of anti-IFN NABs showed persistence of anti-IFN NABs, with titer fluctuation over time, in 27% (3/11) of PLWH.
Conclusions
These results indicate that anti-IFN-α/ω NABs can be detected in the serum of PLWH, reduce the expression of IFN induced retroviral restriction factors and persist in some patients in association with worsening disease, suggesting that assessment of anti-IFN -I NABs could be considered as a novel candidate disease determinant in PLWH.
Table or Figure
![]()